NCT03324022 (TED) is a clinical trial in Graves Ophthalmopathy, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT03324022?

NCT03324022 is sponsored by National Taiwan University Hospital.

What condition does NCT03324022 study?

NCT03324022 studies Graves Ophthalmopathy.

Is NCT03324022 still recruiting?

NCT03324022 is currently status unknown. Last updated 31 October 2017.

Last reviewed 2017-10-31 · How we verify

NCT03324022: TED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease

Status unknown Last updated 31 October 2017

What this trial tests

trial in Graves Ophthalmopathy in 80 participants. Status unknown.

Timeline

25 December 2014

Primary endpoint
25 December 2017

25 December 2020

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	80
Start date	25 December 2014
Primary completion	25 December 2017
Estimated completion	25 December 2020
Sites	1 location across Taiwan

Conditions studied

Graves Ophthalmopathy — all drugs for Graves Ophthalmopathy →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 80, any sex, with Graves Ophthalmopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments. Orbital fibroblasts involves in the pathogenesis of GO by producing glycosaminoglycans and inflammatory cytokines. Since fibroblast growth factors (FGFs) binding to FGF receptors (FGFRs) can induce proliferation and differentiation of fibroblasts, investigators would like to measure the expression of FGFs and FGFRs in GO patients to see if inhibition of FGF-FGFR pathway has potential in treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy.
Shih SR, Liao SL, Shih CW, Wei YH, et al · · 2021 · cited 6× · PMID 31657648 · DOI 10.1080/09273948.2019.1672196

Verify or expand the search:

Other recruiting trials for Graves Ophthalmopathy

Currently open trials in the same condition.

NCT07480720 — Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease · recruiting
NCT05126147 — Hydroxychloroquine in Mild Graves' Orbitopathy · Phase 4 · recruiting
NCT06275373 — The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction · recruiting
NCT05678374 — Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease · recruiting
NCT03131726 — Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) · Phase 3 · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03324022 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 31 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03324022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing